Yousif Capital Management LLC Has $11.74 Million Stock Position in Becton, Dickinson and Company $BDX

Yousif Capital Management LLC lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,735 shares of the medical instruments supplier’s stock after selling 3,178 shares during the period. Yousif Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $11,742,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of BDX. Saudi Central Bank bought a new stake in shares of Becton, Dickinson and Company during the first quarter worth $26,000. Bell Investment Advisors Inc increased its position in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the period. Bank of Jackson Hole Trust raised its holdings in Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 95 shares during the last quarter. WPG Advisers LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $36,000. Finally, CVA Family Office LLC boosted its stake in shares of Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 97 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the sale, the executive vice president directly owned 13,105 shares of the company’s stock, valued at approximately $2,568,973.15. The trade was a 4.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 1,036 shares of company stock worth $197,225. 0.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Jefferies Financial Group raised their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Stifel Nicolaus dropped their price objective on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Finally, Argus raised their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $205.64.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $195.49 on Wednesday. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The business’s 50-day moving average price is $189.82 and its two-hundred day moving average price is $185.88. The firm has a market cap of $55.70 billion, a PE ratio of 33.53, a P/E/G ratio of 1.82 and a beta of 0.25. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.32 billion for the quarter. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be issued a dividend of $1.05 per share. The ex-dividend date is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.